Nicholas von Guionneau, M.D., Ph.D. is a Principal at Catalio Capital Management, LP, where he makes private credit and venture investments in innovative healthcare companies. He focuses on breakthrough medical technologies and clinical care delivery. He represents Catalio as a Board Observer at Amalgam Rx, Character Biosciences, Leo Cancer Care, Orasis Pharmaceuticals, OSPRI, ProSomnus Sleep Technologies, SetPoint Medical, Somethings, Syndeio Biosciences, XRHealth, and ZAP Surgical.
Before joining Catalio, Nicholas was a Postdoctoral Research Fellow at Johns Hopkins Medicine, focused on peripheral nerve regeneration and the development of implantable neurodevices, drug delivery systems, and small protein therapeutics. He began his career as a clinician at Guy’s and St. Thomas’ NHS Trust in London.
He holds a medical degree (MBBS) and a BSc in Medical Sciences (Surgery and Anaesthesia) from Imperial College London, and a Ph.D. in nerve regeneration from Imperial’s Department of Brain Sciences.